SCHEMBL5934219

SCHEMBL5934219

O=C(O)c1cnc(-c2ccccc2Cl)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 1/20 0.49
▸ DHODH Q02127 3/20 0.47
▸ CNR1 P21554 1/20 0.47
▸ PRKDC P78527 1/20 0.46
▸ ATR Q13535 1/20 0.46
▸ KMO O15229 1/20 0.44
▸ P4HTM Q9NXG6 1/20 0.44
▸ ABL1 P00519 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ IDO1 P14902 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ EGLN1 Q9GZT9 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ KMT2A Q03164 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3747046 0.81 ALPL (0.52) ALPLDHODHKMOKDM4ENPC1
SCHEMBL4780143 0.78 EGLN1 (0.56) CNR1P4HTMKDM4EALDH1A1EGLN1
SCHEMBL2929188 0.77 LDHA (0.56) KMOP4HTMKDM4EALDH1A1HPGD
SCHEMBL4652654 0.77 LDHA (0.62) ALPLDHODHP4HTMABL1KDM4E
SCHEMBL29787987 0.76 ATR (0.49) DHODHATRP4HTMKDM4EALDH1A1
SCHEMBL2040123 0.76 ATR (0.49) DHODHATRP4HTMKDM4EALDH1A1
SCHEMBL4450566 0.75 CNR1 (0.72) ALPLDHODHCNR1KMOABL1
SCHEMBL27846546 0.75 IDO1 (0.47) ALPLDHODHPRKDCATRABL1
SCHEMBL3748775 0.75 PDE10A (0.46) ALPLKMOP4HTMKDM4ESMN1; SMN2
SCHEMBL14152227 0.75 CTSA (0.56) ALPLKDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575918-A2 SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-09-21 — — EP claimed
WO-2004056774-A2 SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-08 — — WO claimed
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues NEUROGEN CORPORATION (US) 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues HCAR2, AHR, HCAR3 ALPL 3886/4885DHODH 1968/4885CNR1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback